Tradestie Institutional Equity Comparison Engine

MRNA vs BNTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BNTX Overall Edge

BNTX Captures Institutional Edge (2โ€“2 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BioNTech SE American Depositary Share (BNTX) driven by superior Valuation, Growth & Margin while MRNA counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus BNTX at 7.0x Forward P/E and -55.5% operating margin (-15.1% YoY). In options structure, MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro) against BNTX sits in UNCLASSIFIED (76th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner BNTX
MRNA 23.0x vs BNTX 7.0x Fwd P/E
Growth & Margin Winner BNTX
Op Margin -80.8% vs -55.5% ยท YoY +29.2% vs -15.1%
Momentum & Technical Winner MRNA
1Y +706.5% vs -20.2% ยท 52W Pos 67% vs 3%
Options & Structure Winner MRNA
CONSOLIDATION (52nd %ile IV) vs UNCLASSIFIED (76th %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
BNTX NASDAQ
BioNTech SE American Depositary Share
Biological Products, (No Diagnostic Substances)
$80.96
-0.52% 1D
Market Cap $20.2B
1M Return -9.71%
1Y Return -20.18%
Forward P/E 7.0x
Unified AI Score
41.8 / 100 SELL
Tech 20.0 Fund 42.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +706.45% BNTX -20.18% Spread: +726.63 pp (MRNA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MRNA TTM Op. Margin: -80.8% BNTX TTM Op. Margin: -55.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MRNA vs BNTX. Trailing 12-month operating profitability (MRNA -80.8% vs BNTX -55.5%) and valuation multiples (MRNA 23.0x vs BNTX 7.0x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (3) vs BNTX (7)
Institutional Metric MRNA BNTX Criterion Row Winner
Market Capitalization Scale $80.7B $20.2B Larger Scale MRNA
Trailing P/E Ratio Valuation 23.0x 7.0x Lower Multiple BNTX
Forward P/E Ratio Valuation 23.0x 7.0x Lower Multiple BNTX
Revenue Growth (YoY) Growth +29.2% -15.1% Higher Growth MRNA
Operating Margin (TTM) Profitability -80.8% -55.5% Higher Margin BNTX
Net Profit Margin Profitability -110.5% -60.9% Higher Margin BNTX
Return on Equity (ROE) Capital Efficiency -34.5% -8.1% Higher ROE BNTX
52-Week Range Position Momentum 67% ($22โ€“$281) 3% ($80โ€“$124) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 2.23ฮฒ ยท 78% Vol 0.77ฮฒ ยท 30% Vol Lower Realized Risk BNTX
Unified Institutional Score Composite Signal 40.3 / 100 (SELL) 41.8 / 100 (SELL) Higher Composite BNTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs BNTX Buy Guide
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BNTX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 76th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live BNTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor BNTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.